Abstract 2068
Background
Trastuzumab with cisplatin and fluoropyrimidines(FUs) improved the overall survival of patients with human epidermal growth factor receptor type 2 (HER2)-positive advanced gastric cancer (AGC). S-1 plus oxaliplatin (SOX) is a one of the standard regimen for HER2-negative AGC especially in Japan. However, to date, few studies have evaluated the efficacy and safety of trastuzumab combined with SOX in patients with HER2-positive AGC.
Methods
This is the multi-central, phase II study that is conducted in 10 Japanese institutions. Patients with HER2-positive AGC received S-1 (80mg/m2) twice a day orally on days 1–14, oxaliplatin (130mg/m2) intravenously on day 1, and trastuzumab (course 1, 8mg /kg; course 2-, 6mg/kg) intravenously on day 1 of a 21-day cycle. The primary end point was confirmed response rate (cRR); secondary end points included overall survival (OS), progression-free survival(PFS), and adverse events.The sample size was determined to be 75cases based on a hypothesis of threshold RR of 50% and an expected RR of 65%, 90% power, with an alpha value of 0.1 (one-sided) using the binomial test.
Results
From June 2015 to January 2018, a total of 78 patients were screened, of whom 75 were enrolled and eligible. The median age was 64 years. ECOG PS(0/1);57/18, unresectable/recurrence; 66/9, Gastric/EGJ; 64/11, pathology(tub1/tub2/por/sig); 13/33/24/5, metastatic sites(LNs/liver/peritoneum/lung/bone/others); 40/35/20/9/3/8. The proportion of IHC 3+ was 73.3%. In the full analysis set of 75 patients as of March 2018, cRR was 65.2% (95% confidence interval (CI).52.4–76.5); n = 66: excluding unconfirmed 9 cases; and the disease control rate was 89.4% (95% CI.79.4-95.6). Median OS, PFS, were estimated as 20.6 (95% CI.14.8–30.6) and 9.4(95% CI.7.4-14.7) months, respectively. Major grade 3 or 4 adverse events included sensory neuropathy (14.7%), neutropenia (9.3%), diarrhea (6.7%), and anemia (6.7%). There were no treatment-related deaths.
Conclusions
Trastuzumab in combination with SOX showed promising activity with well-tolerated toxicities in patients with HER2-positive AGC as well as other platinum and FUs. Final analysis based on confirmed response will be reported at the conference.
Clinical trial identification
UMIN000017602,18/5/2015.
Legal entity responsible for the study
The authors.
Funding
Japanese Foundation for Multidisciplinary Treatment of Cancer.
Editorial Acknowledgement
Disclosure
A. Takashima: Grants: Gilead Sciences, Takeda Pharmaceutical Company; Personal fees: Takeda Pharmaceutical Company, Taiho Pharmaceutical Co., Ltd, Merck, Chugai Pharmaceutical Company P, Sanofi K.K., outside the submitted work. S. Kadowaki: Grants: Boehringer Ingelheim, Taiho Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, Eli Lilly Japan. T. Nishina: Grants, Honoraria: Taiho Pharmaceutical, Chugai Pharmaceutical. T.E. Nakajima: Personal financial interests: Eli Lilly, Sanofi, Chugai, Sawai, Bayer, Bristol, Taiho, Merck, Ono, Takeda, Mochida, MSD; Institutional financial interests: Ono, Taiho, A2 Health Care, JCRO, Daiichi-Sankyo, Mediscience Planning. D. Takahari: Honoraria: Taiho Pharmaceutical, Eli Lilly Japan, Chugai Pharmaceutical, Yakult Honsha. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract